-- GoodRx Holdings (GDRX) reported Q1 adjusted earnings late Wednesday of $0.07 per diluted share, down from $0.09 a year earlier.
Analysts polled by FactSet expected $0.07.
Revenue in the three months ended March 31 fell to $194 million from $203 million a year earlier.
Analysts surveyed by FactSet expected $185.4 million.
The company expects full-year revenue of $765 million to $785 million.
Analysts polled by FactSet expect $764.8 million.
GoodRx shares rose 2.1% in after-hours trading.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CGNX delivered solid Q1 2026 results with revenue of $268M (+24% Y/Y), beating consensus by $22M, while adjusted EPS of $0.34 (+113% Y/Y) exceeded expectations by $0.09. Margin expansion continued with adjusted EBITDA margin reaching 26.9% (+1,010 bps Y/Y) and operating margin surging to 22.3% (+1,020 bps), demonstrating exceptional operational leverage. We believe this validates the diversification strategy and suggests industrial automation recovery is gaining momentum. Strong cash generation produced $42.3M in free cash flow (+11% Y/Y), while the company returned $113M to shareholders and maintains $622M in cash with zero debt. Q2 guidance indicates continued momentum with revenue expected at $280M-$300M and adjusted EPS of $0.40-$0.44 (+68% Y/Y at midpoint), above consensus of $0.30. We see the combination of technology leadership, operational excellence, and end-market diversification positioning CGNX well for sustained outperformance through the automation cycle.